In a first‑trimester pregnant woman with a focal uterine contraction on ultrasound but no vaginal bleeding, cervical shortening, or open cervical os, is progesterone therapy (Duphaston – dydrogesterone) indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Progesterone (Duphaston) Is Not Indicated for Isolated Uterine Contractions Without Bleeding

In a first-trimester pregnant woman with a focal uterine contraction visible on ultrasound but no vaginal bleeding, cervical shortening, or open cervical os, progesterone therapy (dydrogesterone/Duphaston) is not indicated. Focal uterine contractions are a normal physiologic finding in early pregnancy and do not represent threatened miscarriage or require pharmacologic intervention when the patient is asymptomatic and the cervix is closed 1.

Understanding Focal Uterine Contractions on Ultrasound

  • Focal uterine contractions appear as transient thickening of the myometrium and are commonly visualized during first-trimester transvaginal ultrasound; they are a normal physiologic phenomenon that resolves spontaneously within 20-30 minutes 1.

  • These contractions do not predict pregnancy loss when the patient has no vaginal bleeding, the cervix is closed, and fetal cardiac activity is present 1.

  • The presence of a contraction should not be confused with subchorionic hemorrhage, which appears as an anechoic or hypoechoic fluid collection between the chorion and uterine wall 2.

Evidence-Based Indications for Dydrogesterone

Dydrogesterone has demonstrated efficacy only in specific clinical scenarios, none of which apply to your patient:

Threatened Miscarriage (Bleeding Present)

  • Dydrogesterone 40 mg stat followed by 10 mg twice daily for one week significantly improved pregnancy continuation rates (95.9% vs 86.3%, p=0.037) in women presenting with first-trimester vaginal bleeding 3.

  • This benefit applies only when vaginal bleeding is present; the study specifically enrolled women with documented bleeding before 13 weeks gestation 3.

Recurrent Miscarriage (History of ≥3 Losses)

  • Dydrogesterone 20 mg daily from ovulation through the first trimester is indicated for women with a history of idiopathic recurrent miscarriage (≥3 consecutive losses) 4, 5.

  • Your patient does not meet this criterion if she has no history of recurrent pregnancy loss 4.

Luteal Phase Insufficiency

  • Dydrogesterone is effective for documented luteal phase deficiency causing infertility, but this diagnosis requires serial progesterone measurements showing inadequate corpus luteum function 5, 6.

  • A single ultrasound finding of uterine contraction does not indicate luteal insufficiency 5.

Why Treatment Is Not Warranted in Your Case

No Evidence of Threatened Miscarriage

  • Threatened miscarriage is defined by vaginal bleeding before 20 weeks with a closed cervix and viable pregnancy; ultrasound findings alone without bleeding do not constitute threatened miscarriage 7.

  • The absence of bleeding, cervical shortening, or cervical dilation indicates a stable pregnancy that does not require progesterone supplementation 1, 7.

Risk of Unnecessary Medicalization

  • Treating normal physiologic findings creates patient anxiety and medicalizes a healthy pregnancy without evidence of benefit 1.

  • No randomized trial has demonstrated benefit of progesterone for asymptomatic ultrasound findings in the absence of bleeding or recurrent loss history 4, 3.

Appropriate Management Algorithm

Immediate Assessment

  • Document fetal cardiac activity using M-mode or video clips (not Doppler in first trimester) to confirm viability 2.

  • Measure crown-rump length to confirm appropriate dating and growth 8.

  • Assess for subchorionic hemorrhage, which would appear as a fluid collection rather than myometrial thickening 2.

Follow-Up Strategy

  • Reassure the patient that focal contractions are normal and do not increase miscarriage risk when bleeding is absent 1.

  • Schedule routine first-trimester follow-up at 10-12 weeks for nuchal translucency screening if desired 8.

  • Instruct the patient to return immediately if vaginal bleeding, severe abdominal pain, or dizziness develops, as these would warrant re-evaluation for threatened miscarriage or ectopic pregnancy 1.

When to Reconsider Progesterone

  • If vaginal bleeding develops, dydrogesterone 40 mg stat then 10 mg twice daily may be considered based on the evidence from threatened miscarriage trials 3.

  • If the patient has a history of ≥3 prior miscarriages that was not initially disclosed, dydrogesterone 20 mg daily would be appropriate 4, 5.

Critical Pitfalls to Avoid

  • Do not prescribe progesterone based solely on ultrasound findings without clinical symptoms of threatened miscarriage 3, 7.

  • Do not confuse focal myometrial contraction with subchorionic hematoma; the former is transient myometrial thickening, the latter is a persistent fluid collection 2.

  • Do not use Doppler ultrasound to assess fetal cardiac activity in the first trimester due to potential bioeffects on the developing embryo; use M-mode or video clips instead 2.

  • Do not perform digital pelvic examination until ultrasound has excluded placenta previa or low-lying placenta, though this is less relevant in first trimester 1.

References

Guideline

Management of Vaginal Bleeding at 5 Weeks of Gestation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Small Subchorionic Hematoma in the First Trimester

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Dydrogesterone in threatened abortion: pregnancy outcome.

The Journal of steroid biochemistry and molecular biology, 2005

Research

Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2005

Research

Dydrogesterone use in early pregnancy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016

Research

Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021

Research

First trimester bleeding.

American family physician, 2009

Guideline

hCG and Progesterone Testing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

When is Duphaston (dydrogesterone) indicated?
What medications are commonly prescribed with Duphaston (dydrogesterone)?
What are the indications and dosing guidelines for Dydrogesterone (progesterone derivative)?
Why am I still experiencing light vaginal bleeding 23 days after a spontaneous miscarriage with low quantitative beta‑human chorionic gonadotropin, negative pregnancy test, endometrial thickness of eight millimeters, and a normal ultrasound?
Is it normal to experience vaginal bleeding at 4 weeks of pregnancy when a menstrual period is typically expected?
What is a reasonable dose of ampicillin/sulbactam for a 66‑kg adult man with normal renal function?
In an asymptomatic patient with hyponatremia due to primary (psychogenic) polydipsia, does adding oral salt supplementation to fluid restriction improve serum sodium correction?
What is the appropriate evaluation, diagnostic work‑up, and management for a patient suspected of aplastic anemia?
In a postmenopausal woman with elevated estradiol, suppressed follicle‑stimulating hormone (FSH) and luteinizing hormone (LH), and low thyroid‑stimulating hormone (TSH) with normal free thyroxine (free T4), what is the likely cause and recommended work‑up?
How should rheumatoid arthritis be managed in a patient with immunoglobulin A (IgA) nephropathy while protecting renal function?
Given a patient with hemoglobin 10.5 g/dL, MCV 80.6 fL, MCH 25.4 pg, normal TIBC, TSH 6.0 µIU/mL with normal free T4, 25‑hydroxyvitamin D 16 ng/mL, fasting glucose 102 mg/dL, HbA1c 5.8 %, triglycerides 266 mg/dL, trace proteinuria, and otherwise normal laboratory studies, what are the likely diagnoses and appropriate management plan?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.